cladribine has been researched along with 2019 Novel Coronavirus Disease in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 31 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battaglia, MA; Brichetto, G; Caleri, F; Callari, G; Carmisciano, L; Clerico, M; Cordera, S; Cordioli, C; Da Rin, G; Di Sapio, A; Ferrò, MT; Franciotta, D; Frau, J; Gandoglia, I; Gazzola, P; Inglese, M; Iodice, R; Landi, D; Lapucci, C; Laroni, A; Liberatore, G; Mannironi, A; Marinelli, F; Pasquali, L; Perego, G; Repice, AM; Salvetti, M; Schiavetti, I; Serrati, C; Signoriello, E; Sormani, MP; Stromillo, ML; Tassinari, T; Uccelli, A; Ulivelli, M | 1 |
| Baker, D; Dobson, R; Giovannoni, G; Kang, AS; MacDougall, A; Schmierer, K | 1 |
| Battistini, L; Furlan, R; Moiola, L; Nicoletti, F; Riva, A; Salvetti, M; Uccelli, A | 1 |
| Cola, G; Di Mauro, G; Grimaldi, A; Landi, D; Marfia, GA; Mataluni, G; Nicoletti, CG | 1 |
| Brill, L; Haham, N; Levin, N; Rechtman, A; Rozenberg, A; Shifrin, A; Vaknin-Dembinsky, A; Zveik, O | 1 |
| Moser, T; Sellner, J; Ziemssen, T | 1 |
| Afanasiev, S; Brill, L; Haham, N; Levin, N; Rechtman, A; Rozenberg, A; Shifrin, A; Vaknin-Dembinsky, A; Zveik, O | 1 |
| Abhari, AP; Baratian, M; Etemadifar, M; Idda, ML; Mahdavi, S; Nouri, H; Pitzalis, M; Salari, M; Sedaghat, N | 1 |
| Albanese, A; Gattorno, G; Schiavetti, I; Sormani, MP | 1 |
| Bernasconi, E; Cantu', M; Disanto, G; Eisler, JJ; Galante, A; Gobbi, C; Keller, F; Mele, F; Sacco, R; Sallusto, F; Zecca, C | 1 |
| Andreone, V; Belardo, M; De Rosa, V; Di Battista, ME; Di Giulio Cesare, D; Ferrara, AL; Liotti, A; Longo, K; Maniscalco, GT; Moreggia, O; Napolitano, M; Prestipino, E; Ranieri, A; Salvatore, S; Vastano, R | 1 |
| Bakkioui, S; Brieva, L; Gil Sánchez, A; González-Mingot, C; Peralta, S; Quibus, L; Ruiz-Fernández, E; San Pedro-Murillo, E; Sancho-Saldaña, A; Solana, MJ; Torres, P | 1 |
| Akçin, R; Arslan, G; Baba, C; Beckmann, Y; Bilge, U; Boz, C; Bünül, SD; Demir, S; Dinç, Ö; Doğan, İG; Efendi, H; Elverdi, T; Gezen, O; Gümüş, H; Gündüz, T; Karabudak, R; Koç, R; Kocazeybek, B; Köseoğlu, M; Kürtüncü, M; Özakbaş, S; Özen, PA; Saip, S; Şen, S; Siva, A; Terzi, M; Tezer, DÇ; Tuncer, A; Turan, ÖF; Tütüncü, M; Uygunoğlu, U; Uzunköprü, C | 1 |
| Adamczyk-Sowa, M; Bartosik-Psujek, H; Chorąży, M; Jamróz-Wiśniewska, A; Kurkowska-Jastrzębska, I; Kułakowska, A; Piasecka-Stryczyńska, K; Pogoda-Wesołowska, A; Puz, P; Rejdak, K; Stępień, A; Słowik, A; Tokarz-Kupczyk, E | 1 |
| Axelsson, M; Brandt, AF; Carlin, G; Gafvelin, G; Grönlund, H; Hessa, T; Högelin, KA; Khademi, M; Kockum, I; Lycke, J; Malmeström, C; Olsson, T; Piehl, F; Rabenstein, M; Thomas, OG | 1 |
| Bloch, S; Golan, D; Lavi, I; Mazar, M; Spierer, R | 1 |
| Arons, E; Burbelo, PD; Cohen, JI; Eager, H; Feurtado, J; Gould, M; James, L; Kreitman, RJ; Mauter, J; Ortiz, OS; Wang, HW; Yu, T; Yuan, CM; Zhou, H | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Berger, B; Dersch, R; Engelhardt, M; Fähndrich, S; Rauer, S; Wehrum, T | 1 |
| Brownlee, WJ | 1 |
| Brescia Morra, V; De Angelis, M; Lanzillo, R; Moccia, M; Petracca, M | 1 |
| Celius, EG | 1 |
| Galazka, A; Jack, D; Nolting, A | 1 |
| Filippi, M; Moiola, L; Nozzolillo, A; Preziosa, P; Rocca, MA | 1 |
| Anwar, MM | 1 |
| Filippi, M; Gelibter, S; Moiola, L; Orrico, M | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Damian, D; Galazka, A; Jack, D; Nolting, A | 1 |
| Azzolini, F; Bellantonio, P; Bruno, A; Buttari, F; Centonze, D; Dolcetti, E; Fantozzi, R | 1 |
| Ethemoğlu, Ö; Seferoğlu, M; Siva, A; Turan, ÖF | 1 |
| Haham, N; Vaknin-Dembinsky, A | 1 |
5 review(s) available for cladribine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
Topics: Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nucleosides; SARS-CoV-2; Tablets | 2022 |
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
Topics: Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunologic Factors; Multiple Sclerosis | 2022 |
COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pandemics | 2022 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article.
Topics: Brain; Cladribine; COVID-19; Cytokine Release Syndrome; Cytokines; Glucocorticoids; Headache; Humans; Immunoglobulins, Intravenous; Immunotherapy; Interferon-beta; Interleukin-6; Nervous System Diseases; Pandemics | 2020 |
26 other study(ies) available for cladribine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Topics: 2019-nCoV Vaccine mRNA-1273; Adult; Antibodies, Monoclonal, Humanized; Antibody Formation; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Rituximab; Treatment Outcome | 2021 |
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2; Vaccination | 2022 |
Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Influenza, Human; Multiple Sclerosis; SARS-CoV-2; Tablets; Vaccination | 2022 |
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus.
Topics: Cladribine; COVID-19; Hepatitis B; Hepatitis B virus; Humans; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis.
Topics: Antibodies, Viral; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Humans; mRNA Vaccines; Multiple Sclerosis; Pandemics; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic | 2022 |
Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Immunoglobulin G; Immunosuppressive Agents; mRNA Vaccines; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2; Tablets; Vaccines, Synthetic | 2022 |
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Topics: Antigens, CD20; Cladribine; COVID-19; Humans; Immunoglobulin G; Leukocytes, Mononuclear; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2 | 2023 |
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Topics: Antibodies, Viral; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Humans; Interferon beta-1a; Multiple Sclerosis; Prospective Studies; SARS-CoV-2; Vaccination | 2022 |
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Multiple Sclerosis; Natalizumab; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Topics: Adult; Cladribine; Cohort Studies; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Poland; Retrospective Studies; Tablets | 2023 |
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Topics: Adaptive Immunity; Alemtuzumab; Antibodies; Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Interferon-gamma; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Vaccination | 2023 |
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
Topics: Adult; Cladribine; COVID-19; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Sphingosine-1-Phosphate Receptors; Vaccination | 2023 |
COVID-19 in patients with classic and variant hairy cell leukemia.
Topics: Antineoplastic Agents; Cladribine; COVID-19; Female; Humans; Leukemia, Hairy Cell; Rituximab | 2023 |
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Topics: Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index | 2020 |
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Topics: Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Humans; Lymphopenia; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
Topics: Adult; Antibodies, Viral; Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Normal antibody response after COVID-19 during treatment with cladribine.
Topics: Antibodies, Viral; Antibody Formation; Cladribine; COVID-19; COVID-19 Drug Treatment; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; SARS-CoV-2 | 2020 |
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets.
Topics: Cladribine; COVID-19; COVID-19 Drug Treatment; Humans; Immunosuppressive Agents; Multiple Sclerosis; SARS-CoV-2; Tablets | 2020 |
COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2021 |
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
Topics: Cladribine; COVID-19; Humans; Multiple Sclerosis; Risk Factors; SARS-CoV-2; Vaccination | 2021 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; SARS-CoV-2; Tablets | 2021 |
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
Topics: Antibodies, Monoclonal, Humanized; Cladribine; COVID-19; COVID-19 Vaccines; Humans; Multiple Sclerosis; SARS-CoV-2 | 2021 |
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; SARS-CoV-2 | 2021 |
COVID-19 in Cladribine-treated patient with multiple sclerosis.
Topics: Cladribine; COVID-19; Drug Administration Schedule; Humans; Immunity, Humoral; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2021 |